IO Biotech, Inc.
IOBT
$0.99
-$0.03-2.94%
NASDAQ
| 12/31/2024 | 09/30/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | -8.38% | 11.28% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 1.66% | 23.09% | |||
| Operating Income | -1.66% | -23.09% | |||
| Income Before Tax | -29.75% | -17.20% | |||
| Income Tax Expenses | 112.92% | -44.12% | |||
| Earnings from Continuing Operations | -30.47% | -16.09% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -30.47% | -16.09% | |||
| EBIT | -1.66% | -23.09% | |||
| EBITDA | -1.65% | -23.17% | |||
| EPS Basic | -30.48% | -16.08% | |||
| Normalized Basic EPS | -29.76% | -17.18% | |||
| EPS Diluted | -30.48% | -16.08% | |||
| Normalized Diluted EPS | -29.76% | -17.18% | |||
| Average Basic Shares Outstanding | 0.00% | 0.00% | |||
| Average Diluted Shares Outstanding | 0.00% | 0.00% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||